<DOC>
	<DOCNO>NCT00141401</DOCNO>
	<brief_summary>To evaluate long-term efficacy safety pregabalin patient diabetic peripheral neuropathy .</brief_summary>
	<brief_title>Safety Efficacy Pregabalin Patients With Diabetic Peripheral Neuropathy .</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must meet inclusion criterion precede doubleblind study Must receive pregabalin amitriptyline placebo doubleblind condition doubleblind condition least first 3 week doubleblind treatment phase precede study . Patients include experienced serious adverse event participate precede doubleblind study , determine related study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>